Go or no go? GSK takes its turn with a novel anaemia class
Amicus and Astrazeneca have notable approaching Pdufa decisions, while a panel for GSK’s daprodustat could change the course of a controversial drug class.
Ocular Therapeutix joins the long-acting race
But the group has a long way to go to set up a showdown with Eylea.
ESC 2022 – factor XI inhibitors crash
Development continues, but multi-billion dollar forecasts for this new anticoagulant class must now be in doubt.
Drug makers leave the pain behind
Developing non-opioid analgesics remains one of the hardest tasks in biopharma.
